EP3867223A4 - Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof - Google Patents

Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof Download PDF

Info

Publication number
EP3867223A4
EP3867223A4 EP19873125.9A EP19873125A EP3867223A4 EP 3867223 A4 EP3867223 A4 EP 3867223A4 EP 19873125 A EP19873125 A EP 19873125A EP 3867223 A4 EP3867223 A4 EP 3867223A4
Authority
EP
European Patent Office
Prior art keywords
alpha
ketoisohexanoate
ketoisovalerate
ketobutyrate
ketoglutarate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19873125.9A
Other languages
German (de)
French (fr)
Other versions
EP3867223A1 (en
Inventor
Michael E. Jung
Jing Huang
Yanpeng XING
Brett E. LOMENICK
Min CHAI
Xudong FU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP3867223A1 publication Critical patent/EP3867223A1/en
Publication of EP3867223A4 publication Critical patent/EP3867223A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19873125.9A 2018-10-17 2019-10-17 Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof Pending EP3867223A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746912P 2018-10-17 2018-10-17
PCT/US2019/056768 WO2020081836A1 (en) 2018-10-17 2019-10-17 Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof

Publications (2)

Publication Number Publication Date
EP3867223A1 EP3867223A1 (en) 2021-08-25
EP3867223A4 true EP3867223A4 (en) 2022-07-13

Family

ID=70284790

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19873125.9A Pending EP3867223A4 (en) 2018-10-17 2019-10-17 Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof

Country Status (3)

Country Link
US (2) US11524948B2 (en)
EP (1) EP3867223A4 (en)
WO (1) WO2020081836A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3867223A4 (en) 2018-10-17 2022-07-13 The Regents of the University of California Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066244A2 (en) * 2004-12-17 2006-06-22 Cash Alan B Method for extending lifespan and delaying the onset of age-related disease
WO2015123229A1 (en) * 2014-02-12 2015-08-20 The Regents Of The University Of California Compositions and methods for treating aging and age-related diseases and symptoms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628803T3 (en) 2013-02-08 2017-08-04 Total Research & Technology Feluy Sa Preparation procedure for cyclic esters and cyclic amides
KR102292058B1 (en) 2015-02-26 2021-08-23 삼성디스플레이 주식회사 Oxide semiconductor device, method of forming an oxide semiconductor device and organic light emitting display device having an oxide semiconductor device
EP3867223A4 (en) 2018-10-17 2022-07-13 The Regents of the University of California Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066244A2 (en) * 2004-12-17 2006-06-22 Cash Alan B Method for extending lifespan and delaying the onset of age-related disease
WO2015123229A1 (en) * 2014-02-12 2015-08-20 The Regents Of The University Of California Compositions and methods for treating aging and age-related diseases and symptoms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020081836A1 *

Also Published As

Publication number Publication date
EP3867223A1 (en) 2021-08-25
US11524948B2 (en) 2022-12-13
US20230174500A1 (en) 2023-06-08
WO2020081836A1 (en) 2020-04-23
US20200325113A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
EP3737665A4 (en) Prodrugs of ketamine, compositions and uses thereof
EP3752612A4 (en) Modified compounds and uses thereof
EP3917526A4 (en) Compounds and uses thereof
EP3746124A4 (en) Compounds and uses thereof
EP3917934A4 (en) Compounds and uses thereof
EP3917517A4 (en) Compounds and uses thereof
EP3917529A4 (en) Compounds and uses thereof
EP3784705A4 (en) Improved continuous microparticle manufacture
EP3917527A4 (en) Compounds and uses thereof
EP3838900A4 (en) 3-aryloxy-3-aryl-propylamine compound and uses thereof
EP4064721A4 (en) Earphone
EP3883562A4 (en) Purified forms of rofecoxib, methods of manufacture and use
EP3941908A4 (en) Compounds and uses thereof
EP3801553A4 (en) Prodrugs of fulvestrant
EP4034535A4 (en) Aza-quinoline compounds and uses thereof
EP3853216A4 (en) Substituted-pyridinyl compounds and uses thereof
EP3768269A4 (en) Compounds and uses thereof
EP3914593A4 (en) Compounds and uses thereof
EP3911322A4 (en) Compounds and uses thereof
EP3947365A4 (en) Substituted-n-heteroaryl compounds and uses thereof
EP3717453A4 (en) Creatine prodrugs, compositions and methods of use thereof
EP3972598A4 (en) Novel uses of crenolanib
EP3946461A4 (en) Xyloglucan-containing prodrugs and methods of manufacture and use thereof
EP3867223A4 (en) Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof
EP3740204A4 (en) Solid forms of fasoracetam

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210513

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07C0069708000

Ipc: A61K0031357000

A4 Supplementary search report drawn up and despatched

Effective date: 20220610

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20220603BHEP

Ipc: C07D 265/32 20060101ALI20220603BHEP

Ipc: C07D 317/32 20060101ALI20220603BHEP

Ipc: C07D 319/12 20060101ALI20220603BHEP

Ipc: C07C 69/66 20060101ALI20220603BHEP

Ipc: C07C 69/708 20060101ALI20220603BHEP

Ipc: A61K 31/34 20060101ALI20220603BHEP

Ipc: A61K 31/421 20060101ALI20220603BHEP

Ipc: A61K 31/341 20060101ALI20220603BHEP

Ipc: A61K 31/42 20060101ALI20220603BHEP

Ipc: A61K 31/22 20060101ALI20220603BHEP

Ipc: A61K 31/6615 20060101ALI20220603BHEP

Ipc: A61K 31/357 20060101AFI20220603BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230419

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240429